Incorporated in Delaware and headquartered in Gaithersburg, Maryland, 20/20 GeneSystems operates as a clinical laboratory testing company providing diagnostic services focused on cancer screening and infectious disease detection. The company's primary offering is OneTest, a multi-cancer early detection blood test designed for cancer screening applications. Additionally, the company markets rapid viral testing products, including COVID-19 rapid test kits such as the Assure COVID-19 IgG/IgM test.
Beyond direct-to-provider testing services, the company operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that provides infrastructure and regulatory support to diagnostic test developers seeking to commercialize products in the U.S. market. The CLIAx platform enables the company to generate revenue through facility access and associated services for diagnostic startups and established companies navigating CLIA certification and market entry.
The company maintains a small operational footprint with 13 full-time employees and operates primarily in the United States. Revenue streams include clinical testing services from OneTest and viral test kits, as well as fees from CLIAx facility access and support services provided to diagnostic developers. The company was founded in 2000 and is classified within the medical devices sector, specifically testing laboratory services.
No 10-K filings found.